Evidence in locomotion test for the functional heterogeneity of ORL‐1 receptors

[1]  S. Ross,et al.  Substituted amphetamine derivatives. II. Behavioural effects in mice related to monoaminergic neurones. , 2009, Acta pharmacologica et toxicologica.

[2]  L. Terenius,et al.  Acquisition, Expression, and Reinstatement of Ethanol-Induced Conditioned Place Preference in Mice: Effects of Opioid Receptor-Like 1 Receptor Agonists and Naloxone , 2003, Journal of Pharmacology and Experimental Therapeutics.

[3]  Steven W. Johnson,et al.  Actions of orphanin FQ/nociceptin on rat ventral tegmental area neurons in vitro , 2002, British journal of pharmacology.

[4]  M. Morari,et al.  Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat , 2002, Neuroscience.

[5]  S. Salvadori,et al.  [Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor , 2002, British journal of pharmacology.

[6]  D G Lambert,et al.  Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors. , 2002, Canadian journal of physiology and pharmacology.

[7]  G. Pasternak,et al.  The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. , 2001, Pharmacological reviews.

[8]  G. Higgins,et al.  Influence of the selective ORL1 receptor agonist, Ro64-6198, on rodent neurological function , 2001, Neuropharmacology.

[9]  G. Calo’,et al.  Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[10]  K. Shieh,et al.  Effects of orphanin FQ on central dopaminergic neuronal activities and prolactin secretion. , 2001, American Journal of Physiology. Regulatory Integrative and Comparative Physiology.

[11]  S. Sesack,et al.  GABA‐containing neurons in the rat ventral tegmental area project to the prefrontal cortex , 2000, Synapse.

[12]  G. Adam,et al.  Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. , 2000, European journal of medicinal chemistry.

[13]  S. Pieretti,et al.  Nociceptin differentially affects morphine-induced dopamine release from the nucleus accumbens and nucleus caudate in rats , 2000, Peptides.

[14]  S. Candeletti,et al.  Effects of an antisense oligonucleotide to pronociceptin and long-term prevention of morphine actions by nociceptin , 2000, Peptides.

[15]  S. Salvadori,et al.  Structure-activity relationships of nociceptin and related peptides: comparison with dynorphin A , 2000, Peptides.

[16]  M. Morari,et al.  Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system , 2000, Peptides.

[17]  G. Adam,et al.  A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Salvadori,et al.  Pharmacology of nociceptin and its receptor: a novel therapeutic target , 2000, British journal of pharmacology.

[19]  K. Tan-No,et al.  Evidence that N-terminal fragments of nociceptin modulate nociceptin-induced scratching, biting and licking in mice , 2000, Neuroscience Letters.

[20]  A. Loizzo,et al.  Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats , 1999, Neuroscience Letters.

[21]  N. Maidment,et al.  Orphanin FQ/Nociceptin Modulation of Mesolimbic Dopamine Transmission Determined by Microdialysis , 1999, Journal of neurochemistry.

[22]  G. Pasternak,et al.  Peripheral orphanin FQ/nociceptin analgesia in the mouse. , 1999, Life sciences.

[23]  T. Nabeshima,et al.  Loss of Antinociception Induced by Naloxone Benzoylhydrazone in Nociceptin Receptor-Knockout Mice* , 1998, The Journal of Biological Chemistry.

[24]  F. Monsma,et al.  Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Pasternak,et al.  Pharmacological characterization of orphanin FQ/nociceptin and its fragments. , 1997, The Journal of pharmacology and experimental therapeutics.

[26]  J. Kuno,et al.  Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor , 1997, The EMBO journal.

[27]  A. Kelley,et al.  Injections of nociceptin into nucleus accumbens shell or ventromedial hypothalamic nucleus increase food intake , 1997, Neuroreport.

[28]  G. Pasternak,et al.  Biochemical evidence for orphanin FQ/nociceptin receptor heterogeneity in mouse brain. , 1997, Biochemical and biophysical research communications.

[29]  L. Terenius,et al.  Nociceptin/Orphanin FQ Microinjected into Hippocampus Impairs Spatial Learning in Rats , 1997, The European journal of neuroscience.

[30]  J. Costentin,et al.  Nociceptin stimulates locomotion and exploratory behaviour in mice. , 1996, European journal of pharmacology.

[31]  F. Monsma,et al.  Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ , 1996, Neurochemical Research.

[32]  N. Maidment,et al.  Intracerebroventricular orphanin FQ/Nociceptin supresses dopamine release in the nucleus accumbens of anaesthetized rats , 1996, Neuroscience.

[33]  J. Xu,et al.  Cloning and expression of a cDNA encoding a mouse brain orphanin FQ/nociceptin precursor. , 1996, The Biochemical journal.

[34]  D. Grandy,et al.  Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor , 1995, Science.

[35]  Marc Parmentier,et al.  Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor , 1995, Nature.

[36]  R. North,et al.  Opioids excite dopamine neurons by hyperpolarization of local interneurons , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[37]  G. E. Alexander,et al.  Functional architecture of basal ganglia circuits: neural substrates of parallel processing , 1990, Trends in Neurosciences.

[38]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[39]  P. Kalivas,et al.  Autoradiographic localization of μ-opioid and neurotensin receptors within the mesolimbic dopamine system , 1989, Brain Research.

[40]  S. Ali,et al.  Biochemical and electrophysiologic effects of thallium poisoning on the rat corpus striatum. , 1977, Toxicology and applied pharmacology.

[41]  W. A. Sexton,et al.  STRUCTURE—ACTIVITY RELATIONSHIPS , 1958, The Journal of pharmacy and pharmacology.

[42]  H. Hall,et al.  The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions , 2004, Psychopharmacology.